These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38353295)

  • 21. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
    Moretti A; Liguori S; Paoletta M; Gimigliano F; Iolascon G
    Adv Ther; 2022 Jul; 39(7):3308-3315. PubMed ID: 35614293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of growth in ambulatory males with Duchenne muscular dystrophy.
    West NA; Yang ML; Weitzenkamp DA; Andrews J; Meaney FJ; Oleszek J; Miller LA; Matthews D; DiGuiseppi C
    J Pediatr; 2013 Dec; 163(6):1759-1763.e1. PubMed ID: 24103921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mobile arm supports in Duchenne muscular dystrophy: a pilot study of user experience and outcomes.
    Cruz A; Callaway L; Randall M; Ryan M
    Disabil Rehabil Assist Technol; 2021 Nov; 16(8):880-889. PubMed ID: 32293211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot test of the GoWoman weight management intervention for women with mobility impairments in the online virtual world of Second Life
    Nosek MA; Robinson-Whelen S; Ledoux TA; Hughes RB; O'Connor DP; Lee RE; Goe R; Silveira SL; Markley R; Nosek TM;
    Disabil Rehabil; 2019 Nov; 41(22):2718-2729. PubMed ID: 29889580
    [No Abstract]   [Full Text] [Related]  

  • 25. Evidence of muscle loss delay and improvement of hyperinsulinemia and insulin resistance in Duchenne muscular dystrophy supplemented with omega-3 fatty acids: A randomized study.
    Rodríguez-Cruz M; Atilano-Miguel S; Barbosa-Cortés L; Bernabé-García M; Almeida-Becerril T; Cárdenas-Conejo A; Del Rocío Cruz-Guzmán O; Maldonado-Hernández J
    Clin Nutr; 2019 Oct; 38(5):2087-2097. PubMed ID: 30420291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased Blood Pressure and Body Mass Index as Potential Modifiable Factors in The Progression of Myocardial Dysfunction in Duchenne Muscular Dystrophy.
    van de Velde NM; Roest AAW; van Zwet EW; Niks EH
    J Neuromuscul Dis; 2019; 6(1):65-73. PubMed ID: 30400104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting parents for the treatment of pediatric obesity in boys with Duchenne muscular dystrophy: a case series.
    Arikian A; Boutelle K; Peterson CB; Dalton J; Day JW; Crow SJ
    Eat Weight Disord; 2010 Sep; 15(3):e161-5. PubMed ID: 21150251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of a multicomponent nutritional supplement on functional outcomes for Duchenne muscular dystrophy: A randomized controlled trial.
    Davidson ZE; Hughes I; Ryan MM; Kornberg AJ; Cairns AG; Jones K; Hutchence M; Sampaio H; Morrison M; Truby H
    Clin Nutr; 2021 Jul; 40(7):4702-4711. PubMed ID: 34237697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Producing a preference-based quality of life measure for people with Duchenne muscular dystrophy: a mixed-methods study protocol.
    Powell PA; Carlton J; Rowen D; Brazier JE
    BMJ Open; 2019 Mar; 9(3):e023685. PubMed ID: 30852532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network.
    Connolly AM; Florence JM; Cradock MM; Malkus EC; Schierbecker JR; Siener CA; Wulf CO; Anand P; Golumbek PT; Zaidman CM; Philip Miller J; Lowes LP; Alfano LN; Viollet-Callendret L; Flanigan KM; Mendell JR; McDonald CM; Goude E; Johnson L; Nicorici A; Karachunski PI; Day JW; Dalton JC; Farber JM; Buser KK; Darras BT; Kang PB; Riley SO; Shriber E; Parad R; Bushby K; Eagle M;
    Neuromuscul Disord; 2013 Jul; 23(7):529-39. PubMed ID: 23726376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T
    Maforo NG; Magrath P; Moulin K; Shao J; Kim GH; Prosper A; Renella P; Wu HH; Halnon N; Ennis DB
    J Cardiovasc Magn Reson; 2020 Dec; 22(1):85. PubMed ID: 33302967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
    Suthar R; Reddy BVC; Malviya M; Sirari T; Attri SV; Patial A; Tageja M; Didwal G; Khandelwal NK; Saini AG; Saini L; Sahu JK; Dayal D; Sankhyan N
    J Pediatr Endocrinol Metab; 2021 May; 34(5):573-581. PubMed ID: 33838091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measuring Duchenne muscular dystrophy impact: development of a proxy-reported measure derived from PROMIS item banks.
    Schwartz CE; Stark RB; Cella D; Borowiec K; Gooch KL; Audhya IF
    Orphanet J Rare Dis; 2021 Nov; 16(1):487. PubMed ID: 34809687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physical training in boys with Duchenne Muscular Dystrophy: the protocol of the No Use is Disuse study.
    Jansen M; de Groot IJ; van Alfen N; Geurts ACh
    BMC Pediatr; 2010 Aug; 10():55. PubMed ID: 20691042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
    JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Energy expenditure, body composition, and prevalence of metabolic disorders in patients with Duchenne muscular dystrophy.
    Saure C; Caminiti C; Weglinski J; de Castro Perez F; Monges S
    Diabetes Metab Syndr; 2018; 12(2):81-85. PubMed ID: 28869151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy.
    Connolly AM; Zaidman CM; Golumbek PT; Cradock MM; Flanigan KM; Kuntz NL; Finkel RS; McDonald CM; Iannaccone ST; Anand P; Siener CA; Florence JM; Lowes LP; Alfano LN; Johnson LB; Nicorici A; Nelson LL; Mendell JR;
    Muscle Nerve; 2019 Jun; 59(6):650-657. PubMed ID: 30706490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of corticotherapy, nutrition, and sleep disorder on quality of life of patients with Duchenne muscular dystrophy.
    Jeronimo G; Nozoe KT; Polesel DN; Moreira GA; Tufik S; Andersen ML
    Nutrition; 2016 Mar; 32(3):391-3. PubMed ID: 26701140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterizing health state utilities associated with Duchenne muscular dystrophy: a systematic review.
    Szabo SM; Audhya IF; Malone DC; Feeny D; Gooch KL
    Qual Life Res; 2020 Mar; 29(3):593-605. PubMed ID: 31811595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.